University of Chicago

Kovler Diabetes Center

Kovler Diabetes Center
900 E. 57th St
8th Floor
Chicago, IL 60637
United States
Call 773-702-3853 Email this location
The University of Chicago is one of twenty-five Type 1 Diabetes TrialNet International Clinical Centers at the forefront of type 1 diabetes research. Led by Principal Investigator, Lou Philipson, MD, the TrialNet team at the University of Chicago is dedicated to preventing type 1 diabetes and stopping disease progression by preserving insulin production before and after diagnosis.

Our Team

Principal Investigators 
Dr. Philipson is an endocrinologist and a leading world authority on diabetes mellitus. In 2011, he was named as one of America’s Top Doctors by U.S. News & World Report magazine, and in 2016 Chicago Magazine named him a Top Doctor in Endocrinology, Diabetes and Metabolism. His research focuses on the biophysical, molecular and genetic aspects of insulin secretion, and the genetics of diabetes. Dr. Philipson was a co-discoverer of insulin gene mutations causing neonatal diabetes, a novel class of mutations causing diabetes through beta-cell ER stress. These mutations are now known to be the second most common cause of permanent neonatal diabetes, as well as rare causes of later-onset diabetes. Dr. Philipson, together with his colleagues (Drs. Graeme Bell, Siri Atma Greeley and Rochelle Naylor) established the first United States registry for monogenic diabetes including neonatal diabetes and Mature Onset Diabetes of the Young (MODY).
Research Coordinators 
Gail Gannon, APN, FNP-C is Manager of Clinical Trials at the Kovler Diabetes Center. She brings more than 20 years of clinical experience in acute care, emergency medicine, and research. Gail has been the driving force behind the expansion of TrialNet and the addition of prevention studies at their center since joining in March of 2015. She serves as sub investigator on all the TrialNet studies, as well as other clinical trials, and assists with management of grants and contracts. Gail is a graduate of DePaul University. She is passionate about improving the lives of people living with Type 1 Diabetes through discoveries in clinical research.

Regional Affiliates

The affiliate sites listed below work with the University of Chicago to offer convenient participation in our research programs
Park Ridge

Advocate Childrens Hospital
1775 Dempster St, Park Ridge, IL 60068

Research Studies

Risk Screening

Pathway to Prevention

If you have a relative with T1D, you’re in a unique position to help us learn more about the disease and how to stop it. The first step is to sign up for Pathway to Prevention screening to determine your risk of developing T1D.


Prevention Study

Abatacept - Closed to Enrollment - Study Ongoing

TrialNet is testing the drug abatacept to see if it can delay or prevent progression of early stage T1D (stage 1 to stage 2) and ultimately prevent clinical diagnosis (stage 3). In earlier studies for people newly diagnosed (stage 3), abatacept helped slow down disease progression.


Teplizumab (Anti-CD3)

We tested the drug teplizumab to see if it could delay or prevent progression of early stage T1D (stage 2) and prevent clinical diagnosis (stage 3). In earlier studies in people newly diagnosed (stage 3), teplizumab helped to prolong insulin production.


Hydroxychloroquine (HCQ)

We are testing the drug hydroxychloroquine (HCQ) to see if it can delay or prevent early stage T1D (stage 1) from progressing to abnormal glucose tolerance (stage 2) and ultimately prevent clinical diagnosis (stage 3). HCQ is already used to reduce symptoms and progression of other autoimmune diseases, such as rheumatoid arthritis and lupus. This is the first study to see if it can prevent or delay T1D.



Long-Term Investigative Follow-Up in TrialNet (LIFT)

Once your study ends, we're still here for you. Participant monitoring and continued involvement helps us learn more about T1D.